BR Biopharma (NASDAQ:BRBI) Announces Earnings Results

BR Biopharma (NASDAQ:BRBI) issued its earnings results on Thursday. The company reported $0.09 earnings per share for the quarter, FiscalAI reports. The firm had revenue of $25.13 million during the quarter.

BR Biopharma Price Performance

NASDAQ BRBI traded down $1.01 during trading on Friday, hitting $10.42. 1,804 shares of the company traded hands, compared to its average volume of 156. BR Biopharma has a 12 month low of $10.21 and a 12 month high of $67.01. The business’s fifty day simple moving average is $11.59.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded BR Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On BR Biopharma

An institutional investor recently bought a new position in BR Biopharma stock. Acuitas Investments LLC bought a new position in shares of BR Biopharma, Inc. (NASDAQ:BRBI) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma accounts for 3.2% of Acuitas Investments LLC’s investment portfolio, making the stock its 7th biggest position.

About BR Biopharma

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.